Pharmacogenetic Variability and Quality of Life in Adolescent Patients with Schizophrenia: The Impact of Metabolizer Status, Symptom Severity, and Adverse Reactions to Antipsychotic Treatment.

J Clin Med · 2026 · PMC13116727 · PMID 42074716

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The metabolic burden showed a trend toward association with a lower QoL, consistent with evidence that cardiometabolic changes emerge early during antipsychotic treatment in youth [ 15 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.